Trademark Search in Canada

HAEMATOKINE

View On IC.GC.CA

REGISTERED

on 5 Mar 2025

Last Applicant/ Owned by

Faron Pharmaceuticals Oy

Joukahaisenkatu 6FI-20520 Turku

Serial Number

2113045 filed on 5^th Feb 2021

Registration Number

TMA1296314 registered on 5^th Mar 2025

Registration expiry Date

5^th Feb 2031

Correspondent Address

ROBIC AGENCE PI S.E.C./ ROBIC IP AGENCY LP

630, boul. René-Lévesque Ouest20e étageMontréal

QUÉBEC

H3B1S6

HAEMATOKINE

Trademark usage description

chemicals preparations for use in the manufacture of pharmaceutical and biotechnological industry and science as well as in photography, agriculture, Read More

Classification Information

Class [001]
Chemicals preparations for use in the manufacture of pharmaceutical and biotechnological industry and science as well as in photography, agriculture, horticulture and forestry; Media for cell culture for use in the biotechnological industry; Media for cell culture for use in non-medical research laboratories; Culture media for microbiology; Cell growth media for growing cells for scientific use; Cultures of bacterial microorganisms for laboratory and scientific research; Cultures of cell media for use in pharmaceutical and biotechnological industry; Cultures of microorganisms for pharmaceutical and biotechnological use; Blood culture media for scientific use; Stem cells for use in pharmaceutical and biotechnological industry; Stem cells for scientific purposes; Stem cells for research purposes.

Classification kind code

Class [005]
Pharmaceuticals, medical and veterinary preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Stem cells for medical or veterinary use; Stem cells for medical purposes; Tumor suppressing agents; Pharmaceutical preparations, namely, antineoplastics; Anti-neoplastic preparations of chemical origin, namely pharmaceutical preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Anti-neoplastic preparations of microbial origin, namely pharmaceutical preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Anti-cancer preparations; Compounds for treating cancer, namely, anti-cancer preparations; Antibodies for medical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Antibodies for medical use to treat inflammation and cancer growth and spread; Adjuvants for medical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Vaccine adjuvants; Biological adjuvants for medical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Anti-inflammatories; Human antigens, namely pharmaceutical antibody preparations for the prevention and treatment of auto-immune diseases; Antitumor drugs; Biological preparations for the treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, multiplication of blood cells; Culture media for medical use, namely, culture media for use in augmentation of blood cells, bone marrow and tissues for medical purposes; Media for bacteriological cultures; Cell growth media for growing cells for medical use; Biological preparations for medical purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Mixed biological preparations for medical purposes, namely, mixed biological preparations for the prevention and treatment of infectious diseases, hematological malignancies, bone marrow dysfunction or suppressions; Biological preparations for veterinary purposes, namely, biological preparations for the treatment of infectious diseases, hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations, namely, immunomodulators; Pharmaceutical preparations, namely, immunostimulants; Injectable pharmaceuticals for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for activating cellular function for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for immunity adjustment for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances with anti-inflammatory properties for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for use in hematology; Pharmaceutical preparations for the prevention of diseases of the immune system in hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for the prevention of disorders of the immune system INin hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the prevention of disorders of the respiratory system; Pharmaceutical preparations for the prevention of inflammatory disorders of the bone marrow; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for the prevention of inflammatory diseases of the bone marrow; Pharmaceutical preparations for the treatment of inflammatory diseases of the bone marrow; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in tissue transplantation; Pharmaceutical products for the treatment of bone diseases; Regulatory proteins for medical use, namely pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Serotherapeutic medicines, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Synthetic peptides for pharmaceutical purposes; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical preparations for the treatment and prevention of ischemic conditions resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions of the bone marrow and allergic conditions; Pharmaceutical preparations for the treatment and prevention of inflammation resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions of the bone marrow and allergic conditions; Pharmaceutical preparations for the treatment and prevention of organ damages resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions of the bone marrow and allergic conditions; Pharmaceutical preparations for treatment and prevention of multi-organ failure, acute lung injury and acute respiratory distress syndrome in adults, adolescents, children, infants and neonates.

Classification kind code

Mark Details

Serial Number

2113045

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 9^th Sept 2022	Search Recorded
Submitted for opposition 135 on 13^th Apr 2022	Amendment to Application
Submitted for opposition 256 on 11^th Apr 2022	Notification of Possible Opposition Sent
Submitted for opposition 48 on 6^th Dec 2021	Agent Changed
Submitted for opposition 15 on 13^th Sept 2021	Correspondence Created
Submitted for opposition 257 on 10^th Jun 2021	Designation Notification - Madrid Protocol
Submitted for opposition 1 on 9^th Jun 2021	Created
Submitted for opposition 31 on 9^th Jun 2021	Formalized
Submitted for opposition 30 on 5^th Feb 2021	Filed
Submitted for opposition 228 on 5^th Feb 2021	International Registration